RA0819

antibody from Oursmab

Targeting: VWF F8VWF

ELISA (Recommended by provider)

Immunocytochemistry (Recommended by provider)

Flow cytometry (Recommended by provider)

Functional assay (Recommended by provider)

Antibody Data

Product number

RA0819

Provider

Oursmab

Product name

Caplacizumab (Biosimilar Reference Antibody) (VWF)

Antibody type

Monoclonal

Description

Caplacizumab is a humanized, bivalent nanobody (single-domain antibody fragment) used for the treatment of acquired thrombotic thrombocytopenic purpura (aTTP). It is marketed under the brand name Cablivi and represents the first-in-class therapeutic specifically approved for this rare, life-threatening thrombotic microangiopathy. Caplacizumab is administered subcutaneously and works by rapidly inhibiting the formation of pathological platelet clumps within small blood vessels. It is used as an adjunct to plasma exchange (the standard therapy) and immunosuppression, significantly reducing the time to platelet count normalization, the risk of recurrent thrombotic events, and mortality associated with aTTP.

Reactivity

Human

Vial size

100 ¦Ìg,1 mg,5 mg,10 mg,25 mg,50 mg,100 mg

Concentration

Bottled at the concentration indicated on the vial.

Storage

Store at -20¡ãC or -80¡ãC. Avoid repeated freeze.